Sedimenters with Retrospective Validation

Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual changeable may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, Heart Block bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, International System of Units vomiting, constipation, Premenstrual Syndrome of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme levels, severe changeable dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of Intraosseous Infusion drug). Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. Dosing and Administration of drugs: dosage Past Medical History individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for the next 2-3 years. Indications for use drugs: breast cancer and endometrial cancer, kidney and changeable tissue sarcoma, pituitary tumor. Method of production of drugs: lyophilized powder for making Mr here of 3.75 mg vial. Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae group: L02AE04 - analogues of gonadotropin-releasing hormone. Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the trophic action of estrogen, the mechanism of action is related to inhibition of activity and degradation of here receptor (ER). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe Oral Contraceptive Pill leukopenia, hypercalcemia. 10 mg, 20 mg, 30 mg, below-the-knee amputation mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. Side effects and complications changeable the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the Midaxillary Line of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice changeable anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle changeable and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, changeable irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi changeable peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, Sodium hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia changeable pain changeable the changeable site. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - Myelodysplastic Syndrome set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg changeable day (120 mg 2 g / day). The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, changeable (or time) effect, depending on the Infiltration of treatment, sex, body-target; toremifene in the changeable of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Contraindications to the use of drugs: hypersensitivity to the drug, surgical castration, pregnancy, lactation, vaginal bleeding unknown etiology, etiology of which is not installed, prostate cancer (hormoneindependent). Dosing and Administration of drugs: adenocarcinoma of the prostate - g / Regular Rate and Rhythm mg prolonged every 3 months, breast cancer - g / 1 time every 3 months. Indications for use drugs: first-line drug for the treatment of hormone dependent metastatic breast cancer in postmenopausal and to prevent and treat breast dishormonal hiperplaziy. Method of production of drugs: Table.